Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

@article{Bahrami2017SwitchingTF,
  title={Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema},
  author={Bobak Bahrami and Thomas E. Hong and Meidong Zhu and Timothy E. Schlub and Andrew A Chang},
  journal={Graefe's Archive for Clinical and Experimental Ophthalmology},
  year={2017},
  volume={255},
  pages={1133-1140}
}
To evaluate the visual and anatomical outcomes following switching therapy from bevacizumab to aflibercept in patients with persistent diabetic macular edema (DME). Patients with DME and central macular thickness (CMT) >300 μm on spectral domain optical coherence tomography (SD-OCT) despite at least 4 intravitreal bevacizumab injections in the prior 6 months were recruited for this prospective, single-armed, single centre, open-label clinical trial. Five loading doses of intravitreal… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Similar Papers

Loading similar papers…